Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/45553
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12133]
Metadata
Show full item record
DIFFERENTIATION-DEPENDENT SUSCEPTIBILITY OF HUMAN MUSCLE CELLS TO ZIKA VIRUS INFECTION
Author
Legros, Vincent
Jeannin, Patricia
Burlaud-Gaillard, Julien
Chaze, Thibault
Gianetto, Quentin Giai
Butler-Brown, Gillian
Mouly, Vincent
Zoladek, Jim
Afonso, Philippe V.
Gonzalez, Mariela Natacha
Matondo, Mariette
Riederer, Ingo
Roingeard, Philippe
Gessain, Antoine
Choumet, Valérie
Emmanuel Ceccaldi, Pierre
Jeannin, Patricia
Burlaud-Gaillard, Julien
Chaze, Thibault
Gianetto, Quentin Giai
Butler-Brown, Gillian
Mouly, Vincent
Zoladek, Jim
Afonso, Philippe V.
Gonzalez, Mariela Natacha
Matondo, Mariette
Riederer, Ingo
Roingeard, Philippe
Gessain, Antoine
Choumet, Valérie
Emmanuel Ceccaldi, Pierre
Affilliation
Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur. Paris, France / Université de Paris. Paris, France / UMR CNRS 3569, Paris, France.
Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur. Paris, France / Université de Paris. Paris, France / UMR CNRS 3569, Paris, France.
INSERM U1259 & Plate Forme IBiSA de Microscopie Electronique, Université François Rabelais and CHRU, Tours, France.
Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS.Institut Pasteur, Paris, France.
Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS.Institut Pasteur, Paris, France / Bioinformatics and Biostatistics Hub, C3BI, USR 3756 IP CNRS, Institut Pasteur, Paris, France.
Sorbonne Université. Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France.
Sorbonne Université. Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.
Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS.Institut Pasteur, Paris, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.
INSERM U1259 & Plate Forme IBiSA de Microscopie Electronique, Université François Rabelais and CHRU, Tours, France.
Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur. Paris, France / Université de Paris. Paris, France / UMR CNRS 3569, Paris, France.
Unité Environnement et Risques Infectieux, Département de Santé Globale, Institut Pasteur, Paris, France
Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur. Paris, France / Université de Paris. Paris, France / UMR CNRS 3569, Paris, France.
Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur. Paris, France / Université de Paris. Paris, France / UMR CNRS 3569, Paris, France.
INSERM U1259 & Plate Forme IBiSA de Microscopie Electronique, Université François Rabelais and CHRU, Tours, France.
Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS.Institut Pasteur, Paris, France.
Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS.Institut Pasteur, Paris, France / Bioinformatics and Biostatistics Hub, C3BI, USR 3756 IP CNRS, Institut Pasteur, Paris, France.
Sorbonne Université. Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France.
Sorbonne Université. Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.
Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS.Institut Pasteur, Paris, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.
INSERM U1259 & Plate Forme IBiSA de Microscopie Electronique, Université François Rabelais and CHRU, Tours, France.
Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur. Paris, France / Université de Paris. Paris, France / UMR CNRS 3569, Paris, France.
Unité Environnement et Risques Infectieux, Département de Santé Globale, Institut Pasteur, Paris, France
Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur. Paris, France / Université de Paris. Paris, France / UMR CNRS 3569, Paris, France.
Abstract
Muscle cells are potential targets of many arboviruses, such as Ross River, Dengue, Sindbis,
and chikungunya viruses, that may be involved in the physiopathological course of the
infection. During the recent outbreak of Zika virus (ZIKV), myalgia was one of the most frequently
reported symptoms. We investigated the susceptibility of human muscle cells to
ZIKV infection. Using an in vitro model of human primary myoblasts that can be differentiated
into myotubes, we found that myoblasts can be productively infected by ZIKV. In contrast,
myotubes were shown to be resistant to ZIKV infection, suggesting a differentiationdependent
susceptibility. Infection was accompanied by a caspase-independent cytopathic
effect, associated with paraptosis-like cytoplasmic vacuolization. Proteomic profiling was
performed 24h and 48h post-infection in cells infected with two different isolates. Proteome
changes indicate that ZIKV infection induces an upregulation of proteins involved in the activation
of the Interferon type I pathway, and a downregulation of protein synthesis. This work
constitutes the first observation of primary human muscle cells susceptibility to ZIKV infection,
and differentiation-dependent restriction of infection from myoblasts to myotubes.
Since myoblasts constitute the reservoir of stem cells involved in reparation/regeneration in
muscle tissue, the infection of muscle cells and the viral-induced alterations observed here
could have consequences in ZIKV infection pathogenesis.
Share